Overview

* 10X Genomics ( TXG ) Q3 revenue of $149 mln beats analyst expectations

* Company reports Q3 net loss of $27.5 mln, improved from prior year

* Operating expenses fell 10% yr/yr, aiding reduction in net loss

Outlook

* 10x Genomics expects Q4 2025 revenue between $154 mln and $158 mln

Result Drivers

* INSTRUMENT REVENUE DECLINE - Decrease in instrument revenue contributed to overall revenue decline

* OPERATING EXPENSES - 10% decrease in operating expenses due to lower personnel and legal costs

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $149 mln $142.50

Revenue mln (14

Analysts

)

Q3 EPS -$0.22

Q3 Net -$27.5

Income mln

Q3 Gross 67%

Margin

Q3 -$32.2

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 12 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for 10X Genomics Inc ( TXG ) is $15.00, about 10.1% above its November 5 closing price of $13.49

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)